NCT00550407View on ClinicalTrials.gov

An Evaluation Of BW430C (Lamotrigine) Versus Placebo In The Prevention Of Mood Episodes In Bipolar I Disorder Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

215

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Bipolar Disorder
Interventions
DRUG

lamotrigine

lamotrigine 100mg/day or 200mg/day

DRUG

Placebo

placebo once daily

Trial Locations (60)

470-1141

GSK Investigational Site, Aichi

260-8677

GSK Investigational Site, Chiba

272-8516

GSK Investigational Site, Chiba

289-2511

GSK Investigational Site, Chiba

800-0217

GSK Investigational Site, Fukuoka

802-0001

GSK Investigational Site, Fukuoka

802-0006

GSK Investigational Site, Fukuoka

807-8555

GSK Investigational Site, Fukuoka

810-0004

GSK Investigational Site, Fukuoka

812-8582

GSK Investigational Site, Fukuoka

814-0180

GSK Investigational Site, Fukuoka

815-0041

GSK Investigational Site, Fukuoka

830-0011

GSK Investigational Site, Fukuoka

375-0017

GSK Investigational Site, Gunma

377-0055

GSK Investigational Site, Gunma

734-8551

GSK Investigational Site, Hiroshima

737-0023

GSK Investigational Site, Hiroshima

002-8029

GSK Investigational Site, Hokkaido

060-0042

GSK Investigational Site, Hokkaido

060-8648

GSK Investigational Site, Hokkaido

064-0946

GSK Investigational Site, Hokkaido

311-3193

GSK Investigational Site, Ibaraki

216-8511

GSK Investigational Site, Kanagawa

221-0835

GSK Investigational Site, Kanagawa

224-8503

GSK Investigational Site, Kanagawa

225-0011

GSK Investigational Site, Kanagawa

231-0023

GSK Investigational Site, Kanagawa

238-0042

GSK Investigational Site, Kanagawa

861-8002

GSK Investigational Site, Kumamoto

616-8421

GSK Investigational Site, Kyoto

510-8575

GSK Investigational Site, Mie

515-0044

GSK Investigational Site, Mie

634-8522

GSK Investigational Site, Nara

700-8558

GSK Investigational Site, Okayama

533-0005

GSK Investigational Site, Osaka

569-1041

GSK Investigational Site, Osaka

570-8507

GSK Investigational Site, Osaka

583-0884

GSK Investigational Site, Osaka

590-0018

GSK Investigational Site, Osaka

874-0011

GSK Investigational Site, Ōita

879-5593

GSK Investigational Site, Ōita

879-7501

GSK Investigational Site, Ōita

842-0192

GSK Investigational Site, Saga

332-0012

GSK Investigational Site, Saitama

100-0006

GSK Investigational Site, Tokyo

113-8603

GSK Investigational Site, Tokyo

151-0053

GSK Investigational Site, Tokyo

152-0012

GSK Investigational Site, Tokyo

154-0004

GSK Investigational Site, Tokyo

154-0012

GSK Investigational Site, Tokyo

166-0003

GSK Investigational Site, Tokyo

170-0002

GSK Investigational Site, Tokyo

173-0037

GSK Investigational Site, Tokyo

180-0005

GSK Investigational Site, Tokyo

183-0042

GSK Investigational Site, Tokyo

187-8551

GSK Investigational Site, Tokyo

190-0023

GSK Investigational Site, Tokyo

680-0011

GSK Investigational Site, Tottori

682-0023

GSK Investigational Site, Tottori

999-2221

GSK Investigational Site, Yamagata

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00550407 - An Evaluation Of BW430C (Lamotrigine) Versus Placebo In The Prevention Of Mood Episodes In Bipolar I Disorder Patients | Biotech Hunter | Biotech Hunter